Aethlon Medical (AEMD) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for February 19, 2026, to be held virtually via webcast.

• Supplement addresses changes to the exercisability of Pre-Funded Warrants issued in a December 2025 private placement.

• Amendments allow immediate exercise of Pre-Funded Warrants, removing the prior requirement for stockholder approval as a contractual condition.

• No changes to the total number of shares issuable or other economic terms of the Pre-Funded Warrants.

Voting matters and shareholder proposals

• Proposal No. 5 seeks approval for issuance of up to 1,662,553 shares of Common Stock under Nasdaq Listing Rule 5635(d).

• Stockholder approval is still required for Common Warrants and Placement Agent Warrants.

• Board recommends voting "FOR" Proposal No. 5.

• Previously submitted proxies remain valid unless revoked or changed by shareholders.

Board of directors and corporate governance

• Secretary James Frakes issued the supplement on behalf of the Board.

• Board continues to recommend approval of Proposal No. 5.